The Dup15q Syndrome market growth is driven by factors like increase in the prevalence of Dup15q Syndrome, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Dup15q Syndrome market report also offers comprehensive insights into the Dup15q Syndrome market size, share, Dup15q Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dup15q Syndrome market size growth forward.
Some of the key highlights from the Dup15q Syndrome Market Insights Report:
- Several key pharmaceutical companies, including Q-State Biosciences, Ovid Therapeutics, Radius Health, Zogenix, and others, are developing novel products to improve the Dup15q Syndrome treatment outlook.
- The total Dup15q Syndrome market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Dup15q Syndrome market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Dup15q Syndrome Market Landscape
Dup15q Syndrome Overview
15q duplication syndrome (maternal dup15q) is characterized by hypotonia and motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy including infantile spasms. Rarely, maternal dup15q may also be associated with psychosis or sudden unexplained death. Those with a maternal isodicentric 15q11.2-q13.1 supernumerary chromosome are typically more severely affected than those with an interstitial duplication. The diagnosis of maternal dup15q is established by detection of at least one extra maternally derived copy of the Prader-Willi/Angelman critical region, a region approximately 5 Mb long within chromosome region 15q11.2-q13.1. The extra copy or copies most commonly arise by one of two mechanisms:
A maternal isodicentric 15q11.2-q13.1 supernumerary chromosome – idic(15) – typically comprising two extra copies of 15q11.2-q13.1 and resulting in tetrasomy for 15q11.2-q13.1 (~60-80%);
A maternal interstitial 15q11.2-q13.1 duplication that typically includes one extra copy of 15q11.2-q13.1 within chromosome 15, resulting in trisomy for 15q11.2-q13.1 (~20-40%).
Do you know the treatment paradigms for different countries? Download our Dup15q Syndrome Market Sample Report
Dup15q Syndrome Epidemiology Segmentation
DelveInsight’s Dup15q Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dup15q Syndrome historical patient pools and forecasted Dup15q Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dup15q Syndrome Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Dup15q Syndrome Prevalence
- Age-Specific Dup15q Syndrome Prevalence
- Gender-Specific Dup15q Syndrome Prevalence
- Diagnosed and Treatable Cases of Dup15q Syndrome
Visit for more @ Dup15q Syndrome Epidemiological Insights
Dup15q Syndrome Treatment Market
The Dup15q Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dup15q Syndrome market trends by analyzing the impact of current Dup15q Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Dup15q Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dup15q Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Dup15q Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Dup15q syndrome Emerging Drugs
RAD011: Radius Health
Investigational drug RAD011 is a pharmaceutical-grade synthetic cannabidiol oral solution, manufactured utilizing traditional pharmaceutical manufacturing processes. The product has purity specifications that meet standardized regulatory and quality control requirements and, compared to the process of developing a plant-derived product, the synthetic manufacturing process usually enables increased consistency and greater precision in the product supply. RAD011 has been assessed in over 125 patients across multiple indications and has potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas. Radius plans to study RAD011 in patients with Angelman syndrome, Prader-Willi syndrome, and infantile spasms.
Dup15q Syndrome Key Companies
- Q-State Biosciences
- Ovid Therapeutics
- Radius Health
- Zogenix
For more information, visit Dup15q Syndrome Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Dup15q Syndrome Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Dup15q Syndrome, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Dup15q Syndrome epidemiology in the 7MM
- Dup15q Syndrome marketed and emerging therapies
- Dup15q Syndrome companies
- Dup15q Syndrome market drivers and barriers
Key Questions Answered in the Dup15q Syndrome Market Report 2032:
- What was the Dup15q Syndrome market share distribution in 2019, and how would it appear in 2032?
- What is the total Dup15q Syndrome market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Dup15q Syndrome market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Dup15q Syndrome market projected to expand at 7MM?
Table of Contents:
1 Dup15q Syndrome Market Key Comprehensive Insights
2 Dup15q Syndrome Market Report Introduction
3 Competitive Intelligence Analysis for Dup15q Syndrome
4 Dup15q Syndrome Market Analysis Overview at a Glance
5 Executive Summary of Dup15q Syndrome
6 Dup15q Syndrome Epidemiology and Market Methodology
7 Dup15q Syndrome Epidemiology and Patient Population
8 Dup15q Syndrome Patient Journey
9 Dup15q Syndrome Treatment Algorithm, Dup15q Syndrome Current Treatment, and Medical Practices
10 Key Endpoints in Dup15q Syndrome Clinical Trials
11 Dup15q Syndrome Marketed Therapies
12 Dup15q Syndrome Emerging Therapies
13 Dup15q Syndrome: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Dup15q Syndrome
16 Dup15q Syndrome Market Key Opinion Leaders Reviews
18 Dup15q Syndrome Market Drivers
19 Dup15q Syndrome Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Dup15q Syndrome Epidemiology 2032
DelveInsight’s “Dup15q Syndrome – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dup15q Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Dup15q Syndrome Pipeline 2023
“Dup15q Syndrome Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dup15q Syndrome market. A detailed picture of the Dup15q Syndrome pipeline landscape is provided, which includes the disease overview and Dup15q Syndrome treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/